Evidence map›Paper›PMID 42428509›Full record

ReviewFrontiers in pharmacology2026

Pharmacoepidemiology unpacked: a roadmap for junior researchers.

Alyaa M Ajabnoor

Abstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Alyaa M AjabnoorDepartment of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pharmacoepidemiology is an evolving discipline at the intersection of pharmacology, epidemiology, and clinical medicine, playing a pivotal role in evaluating real-world medication use, safety, and effectiveness. This review aims to provide early-career researchers with a structured and practical roadmap to navigate the field. The manuscript is organized around a step-by-step research framework, guiding readers from formulating a clear research question and protocol development, through study design selection and identification of appropriate data sources, to the operationalisation of key variables, including exposures, outcomes, and covariates. It further addresses statistical analysis and modelling, followed by critical evaluation of biases and limitations, and concludes with reporting and interpretation of findings. This integrated structure reflects the real-world progression of pharmacoepidemiologic research and supports coherent study planning and execution. Recent advancements in the field include the increasing use of real-world data, causal inference approaches, and advanced analytical methods, supported by large healthcare databases and evolving data infrastructures. In addition, the adoption of reporting standards such as STROBE and RECORD has improved transparency, reproducibility, and methodological rigor. This review provides an integrated, workflow-oriented perspective that bridges methodological concepts with practical application, equipping early-career researchers to design robust studies and contribute meaningfully to evidence-based drug safety and effectiveness research.

Indexed as

observational researchpharmacoepidemiologypharmacovigilancereal-world evidencestudy design

Identifiers

PMID42428509
PMCPMC13346231

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.